Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPACT-MI
MOH_2021-01-14_009664Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Empagliflozin with Placebo (2 arms). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2021-01-14_009664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-14_009664.